Mineralys Therapeutics, Inc.
corporate_fare Company Profile
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for MLYS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for MLYS spans 10-Q, 8-K, 144, 424B5.
Recent high-impact activity:
- Mineralys Q3 Loss Widens to $57.3M as Launch Spending Builds; $624.7M Cash
- Mineralys Q3 Loss Widens to $57.3M as Lorundrostat Launch Build-Out Accelerates Ahead of Dec 22 PDUFA
- Mineralys Closes Tanabe Termination, Owns Lorundrostat IP Outright but Keeps $265M Milestones
- Lorundrostat Cuts BP 7.5 mmHg and Proteinuria in Phase 2 CKD Trial
- Lorundrostat Cuts Albuminuria 52% in CKD as FDA Decision Nears
Financial Snapshot
Short Interest & Short Volume
4.95 days to coverFINRA reported short interest of 7,687,327 shares in MLYS as of the October 30, 2026 settlement, a 3.4% increase from the prior period — about 5.0 days to cover at its recent average daily volume. On November 20, 2026, 45.8% of MLYS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for MLYS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-03.
Underwritten Common Stock Offering Priced · Significant Capital Raise
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →